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CASE REPORT

A rare case of Epstein–Barr virus-related plasmacytoma
involving maxillary sinus mucosa
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Key Clinical Message
Extramedullary plasmacytomas, Epstein–Bar virus (EBV) associated, are rarely
encountered and usually have a fairly good clinical outcome. EBV+ plasmacytoma
may cause a diagnostic dilemma as it phenotypically resembles an aggressive plasmablastic lymphoma (PBL). Herein, we report a unique case with maxillary EBV+
plasmacytoma from a 76-year-old immunocompetent individual.
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Introduction
Extramedullary plasmacytomas are mature monoclonal
plasma cell neoplasms that usually involve the upper respiratory tract of immunocompetent individuals and are
infrequently Epstein–Barr virus (EBV) related [1, 2]. They
typically follow a clinically indolent course and are usually
treated with radiation therapy or limited chemotherapy
regimens [1, 2]. Plasmablastic lymphomas (PBL), on the
other hand, are clinically aggressive B-cell neoplasms,
which usually lack B-cell markers but express plasma cell
markers [3, 4]. PBL was first described in the oral cavity
of human immunodeficiency virus (HIV)-positive individuals and now is known to occur in other immunocompromised states and less often in immunocompetent
individuals [3, 4]. The Ki-67 proliferative index of PBL is
usually high and often >60% [3]. EBV-encoded RNA
(EBER) is detectable in 75–100% of PBL but only in
approximately 10% of plasmacytomas [4, 5]. Unlike plasmacytomas, PBL has a higher 5-year mortality rate
despite aggressive treatment [3, 4]. Clinically and histologically, plasmacytoma and PBL can be confidently
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distinguished, but a diagnostic dilemma may occur when
a plasmacytoma is EBV positive and presents with unusual clinical or morphological features. An accurate diagnosis is critical for appropriate therapeutic decisions and
prognosis.

Case Report
Herein, we report a unique case of EBV-related extramedullary plasmacytoma of maxillary sinus in an immunocompetent, HIV-negative patient with characteristic
clinical and histological features, excellent outcome, and
long-term follow-up.
A 76-year-old male patient was diagnosed with a
T2N2bM0 squamous cell carcinoma of the left hypopharynx, which was treated with radiation and chemotherapy
(completed December 2011). In March 2014, he presented
again after two episodes of epistaxis. A positron emission
tomography–computed tomography (PET/CT) scan at that
time showed 18F-fludeoxyglucose uptake in the right maxillary sinus, where a 4.2 9 4.4 9 3.9 cm expansile soft tissue mass had extended into the medial sinus wall
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(Fig. 1A). There was no general lymphadenopathy and
hepatosplenomegaly by imaging studies. A sinus curettage
was performed by an outside facility, consistent with “plasmacytoma.” The patient then presented to our center for
further recommendations and treatment. A serum protein

electrophoresis with immunofixation at that time showed
an IgG-kappa monoclonal gammopathy, whereas the urine
protein electrophoretic pattern was within normal limits. A
staging bone marrow biopsy in May 2014 was negative for
malignancy, and a bone scan did not show any suspicious
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Figure 1. (A) CT scan of head showed 4.2-mm mass located at the right nasal cavity. (B) Biopsy revealed mucosa-covered polypoid mass (H&E,
x40). (C) Medium power view of the H&E section showed numerous mature plasma cells with round to oval, eccentrically located nuclei with
condense chromatin and abundant eosinophilic cytoplasm. Occasional enlarged plasma cells with hyperchromasia or binucleation are identified
(H&E, x200). (C–H) Immunohistochemical stains highlight that plasma cells are strongly and diffusely positive for CD138 (D, x200) and kappa light
chain (E, x100) and negative for lambda light chain (F, x100), CD8 (G, x100) and CD20 (H, x100). (I) In situ hybridization (ISH) with EBV-encoded
RNA probe revealed strong hybridization signals (x200). (J and K) Proliferation by Ki67 is slightly variable, ranging from 30% (J, x100) to focally
up to 60% (K, x100).
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lytic lesions. Pathology slides, prepared outside our center,
were reviewed to confirm the diagnosis.
The provided hematoxylin and eosin (H&E) sections
showed a polypoid proliferation of predominantly mature
plasma cells with a focal subset of atypical, less matureappearing plasma cells, which did not appear to infiltrate
into the surrounding mucosa or submucosal soft tissue.
Only a small subset of plasma cells showed slightly
increased nuclear-to-cytoplasmic ratio and less condensed
chromatin (Fig. 1B and C).
We analyzed the samples with a panel of immunohistochemical stains. The plasma cells were positive for CD138
(Fig. 1D), kappa light chain (Fig. 1E), CD56 (focal),
CD117 (focal), and MYC (subset) and negative for
lambda light chain (Fig. 1F), CD3, CD20 (Fig. 1H), and
EBV-LMP. Many CD8-positive T cells were present in the
background (Fig. 1G). The Ki-67 proliferation index, by
manual morphometric determination, was variable, ranging from 30% to 60%, with the higher index areas corresponding to areas of less mature-appearing plasma cells
(Fig. 1J and K). Chromogenic in situ hybridization studies showed the tumor cells to be positive for EBER
(Fig. 1I). A MYC immunostain showed focal positivity
(overall 5% of the total cellularity)(not shown). A FISH
study using a MYC break-apart probe, performed on a
section of paraffin-embedded tissue, revealed intact signals, indicating no MYC gene rearrangement. A bone
marrow biopsy, together with flow cytometry and
immunohistochemical stains, showed no evidence of clonal plasma cells. Cytogenetic and molecular studies performed on the bone marrow were normal (46,XY). The
overall findings were consistent with an EBV-related
extramedullary plasmacytoma.
Treatment consisted of definitive radiation therapy
(180–4500 cGy) to his right sinus over the months following, which he tolerated extremely well. A computed
tomography scan performed in July 2016, 2 years after
the initial diagnosis, showed no evidence of recurrent
tumor. The patient is currently asymptomatic and doing
well from a clinical standpoint, with no evidence of recurrent disease.

Although a few cases of plasmacytoma with a higher proliferative index and starry-sky appearance have been
reported, follow-up suggests that these cases were either
the initial presentation of myeloma, or could have been
more appropriately classified as PBL [1, 4].
Although the exact role of EBV in pathogenesis
remains unclear [2, 5], many believe that PBL may occur
as a transformation from preexisting plasmacytoma after
EBV infection [5]. Ambrosio et al. recently reported a
rare case of plasmablastic transformation of a preexisting
plasmacytoma in an immunocompetent 74-year-old man
initially diagnosed with an EBV-positive, MYC-negative
plasmacytoma, who experienced multiple relapses with
increasing proportions of EBV-encoded RNA-positive and
MYC-positive cells by immunohistochemistry (FISH negative) [5]. A recent study from Motes-Moreno’s group
showed genetic aberrations of MYC (approximately 46%
translocation and 11% amplification) were detected in
patients with PBL (36 cases) that lead to MYC protein
overexpression [6]. In contrast to most previously
reported cases of EBV-positive plasmacytomas, our case
had a focally higher Ki-67 proliferative index of up to
60% and had MYC expression (>5%) by immunohistochemistry, warranting a FISH study for MYC gene rearrangement. Negative MYC gene rearrangement favored a
less aggressive clinical course and a lower likelihood of
transformation to PBL. In addition, a subsequent EBV
PCR study, performed on a peripheral blood sample, was
negative. The patient responded well to local radiation
and adjuvant chemotherapy and showed no recurrent disease to date, 2.5 years after initial diagnosis.
In conclusion, as shown in here, because extramedullary plasmacytomas are infrequently EBV related, clinically and histologically, a diagnostic dilemma regarding
differentiation from PBL, which is typically EBV positive,
can occur. A complete clinical and immunohistological
investigation should help support an accurate diagnosis,
which has substantial therapeutic and prognostic implications.
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Only a handful of EBV-positive plasmacytoma cases have
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